VILLEJUIF, FRANCE-
After more than 25 randomized
trials, the effect of amifostine(Drug information on amifostine)
(Ethyol) on the survival of patients
treated with radiotherapy is still
unknown. This is because most of
the trials were neither designed
nor powered to detect small survival
differences and had followup
periods that were either short
(less than 2 years) or very short (a
few months), according to Jean
Bourhis, MD, PhD, of the departments
of biostatistics and radiotherapy,
Institut Gustave-Roussy,
Villejuif, France. To assess whether
this drug is associated with a
survival benefit in radiotherapytreated
patients, he and his col-
leagues are conducting a metaanalysis
of amifostine trials.
Nonmetastatic Ca Only
Selection criteria include properly
randomized trials performed
between 1990 and June 2002, in
which patients were randomized
to receive radiotherapy or chemoradiotherapy
plus amifostine, or
to radiotherapy or chemoradiotherapy
without amifostine. Patients
had nonmetastatic head and
neck, lung, or pelvic carcinomas.
Updated data are being collected
for all randomized patients from
published and unpublished trials,
and extensive checking and validation
will be done to ensure the
integrity of randomization and foloni
low-up. Dr. Bourhis noted "pseudorandomization"
might happen
in some clinical trials.
Tumor Control an Endpoint
The primary endpoint of the
meta-analysis is the effect of amifostine
on survival. The secondary
endpoint is effect on tumor control.
The meta-analysis will include
more than 2,000 patients from 8
trials of non-small-cell lung cancer,
13 of head and neck cancer,
and 7 of pelvic cancer. The investigators
expect to report results in
about 1 year.
Dr. Bourhis's decision to include
unpublished trials evoked some
questions during the discussion
period. "We are trying to avoid
publication bias in favor of positive
trials," he said. "We have to be
careful not to avoid trials that have
not been published because
the results were not exactly as
expected."
